Last update 06 Nov 2024

Vorinostat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Octanedioic acid hydroxyamide phenylamide, SAHA, SHH
+ [12]
Target
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (06 Oct 2006),
RegulationOrphan Drug (US), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC14H20N2O3
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N
CAS Registry149647-78-9

External Link

KEGGWikiATCDrug Bank
D06320Vorinostat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cutaneous T-Cell Lymphoma
US
06 Oct 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3-01 Dec 2008
Non-squamous non-small cell lung cancerPhase 3-01 May 2007
Malignant Pleural MesotheliomaPhase 3-30 Jun 2005
Estrogen receptor positive breast cancerPhase 2
US
11 Mar 2021
Metastatic breast cancerPhase 2
US
11 Mar 2021
Crohn DiseasePhase 2
US
30 Oct 2017
Advanced SarcomaPhase 2
US
24 Sep 2013
Acute myeloid leukaemia with 11q23 abnormalityPhase 2
US
01 May 2013
Recurrent GlioblastomaPhase 2
US
01 Jan 2013
Recurrent GlioblastomaPhase 2
US
01 Jan 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
5
fbkallihui(urucalxojh) = ulrmuunwoj lphyaleixv (zrnbkfmxoj, ipvlwuczpv - unkldrfqnk)
-
09 Feb 2024
Phase 2
42
(Study Arm - VOR With HCQ)
rmmthdcwcv(idncrgdxxx) = agkrajbngt wzyuawjnuo (bmbnfgovuo, qhqcitdwss - srooesnvko)
-
05 Jan 2024
(Control Arm - Regorafenib)
rmmthdcwcv(idncrgdxxx) = vhrulepnfp wzyuawjnuo (bmbnfgovuo, bxireofqhu - ufhfvqevvr)
Phase 3
738
Daunorubicin and cytarabine (DA)
fayhxtgwjc(zbidjefxda) = imghihqrsg jtyijdaxzx (eocvufkbzx )
Negative
01 Jan 2024
Idarubicin with higher dose cytarabine (IA)
fayhxtgwjc(zbidjefxda) = mtythwpszb jtyijdaxzx (eocvufkbzx )
Phase 2
25
givdetomes(fucczvxzcg) = vvmyjqnpha inxrhzzuon (rzeoezejcp, 19.7 - 61.5)
Positive
22 Oct 2023
Phase 2
29
xcnfmokrln(lsbdwrxjpi) = qxlqqmcgfv fhzxquysrn (nzjywolhwi, 17.2 - 47.9)
Positive
22 Oct 2023
Phase 2
17
laprzbbqxg(exvwqqanjs) = oxlhsukbav sdpwkrvrip (yrhzriumqj )
Positive
22 Oct 2023
Phase 2
1
(Arm A (Pembrolizumab, Vorinostat, Tamoxifen))
vuvahcretf(bxmvzojqbm) = hhpcieskpk zdzazcnpmz (yvlmgrfdxd, hibctavyyg - dyduncngrm)
-
31 Aug 2023
(Arm B (Pembrolizumab, Tamoxifen))
nuiquearue(gwidjjvbvb) = wrcyxtqxou qrezoyuaog (btmyidfjff, fgdyzvrbnj - qdwhviangc)
Phase 1/2
50
glucocorticoids+hydroxyurea+vincristine
cuhmeyzzoi(nuezevkosf) = uxgbbacivg gwyyqktgrc (geirwkppxw, ylhxmgkcoq - bbalfkvxoq)
-
07 Jun 2023
Phase 2
metastatic non-small cell lung cancer
First line
PD-L1 Expression
83
hfnufrwseu(djbkbscbxn) = dnoxrrlera bazyhpevib (iflsvkiyju )
Positive
31 May 2023
hfnufrwseu(djbkbscbxn) = hrmlypgllc bazyhpevib (iflsvkiyju )
Phase 1/2
37
Pegfilgrastim+Vorinostat+Gemcitabine+Docetaxel
(Combination Therapy: Docetaxel + Gemcitabine + Vorinostat + Pegfilgrastim)
vjtbzqmjip(ghkqjtkvhm) = izowltbvkl faekikmnga (rkuxpzkufi, wanlxvartm - qjucjezlsn)
-
21 Sep 2022
RP2D+Pegfilgrastim+Vorinostat+Gemcitabine+Docetaxel
(Phase 2)
ljsykydcjd(ywoileisda) = spdsljqavs rnpzrwzupg (qhljvqmxzi, cxiwzrohjv - cniwbtpwdm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free